Finance Watch: Mega-Rounds Help 2024 Biopharma VC Funding Exceed 2023
Big Series A Rounds: $95m for Jade, $92m For Kivu
Private Company Edition: Despite a third quarter dip, venture capital investment in biopharma in 2024 is on track to beat 2023, new data confirm. VC mega-rounds of $100m or more helped boost the total, including recent financings totaling $175m for Alpha-9 and $112m for AvenCell.
